Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 10/30/2013 -- Reportstack, provider of premium market research reports announces the addition of Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 market report to its offering
Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022


Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Nimenrix (Meningococcal groups A, C, Y, W-135 polysaccharide tetanus toxoid conjugate vaccine) is the brand name for GSKs tetravalent conjugate vaccine sold in the EU to protect children, adolescents, and adults against four serogroups of N. meningitidis (A, C, Y, W-135) that cause invasive meningococcal infections. Approved in the EU 2012, Nimenrix is the first tetravalent conjugate vaccine available in Europe for patients between 12 and 23 months of age.


- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nimenrix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nimenrix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nimenrix performance
- Obtain sales forecast for Nimenrix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604